<PAGE> 1
----------------------------
OMB APPROVAL
----------------------------
OMB Number: 3235-0145
UNITED STATES Expires: October 31, 1997
SECURITIES AND EXCHANGE COMMISSION Estimated average burden
WASHINGTON, D.C. 20549 hours per response ....14.90
----------------------------
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. __________)*
Meridian Medical Technologies, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
589658103
-------------------------------------------------------
(CUSIP Number)
Robert G. Foster 4 Milk Street Portland ME 04101 (207) 780-0904
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
November 20, 1996
-------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the statement [ ]. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
SCHEDULE 13D
- ------------------- -------------------
CUSIP NO. 589658103 PAGE____OF____PAGES
- ------------------- -------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
BioVenture Partners Limited Partnership
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
00
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO [ ]
ITEMS 2(d) or 2(e)
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES -------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 583,003*
EACH -------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON 0
WITH -------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
583,003*
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
583,003*
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.9%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN *Beneficial ownership expressly disclaimed.
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
2 of 7
<PAGE> 3
Schedule 13D Bioventure Partners Limited Partnership
ITEM 1. SECURITY AND ISSUER. The class of securities to which this Schedule
relates is Common Stock, $.10 par value of Meridian Medical Technologies, Inc.
(f/k/a Survival Technology, Inc.), a Delaware corporation (the "Issuer"). The
address of the principal executive office of the Issuer is:
Meridian Medical Technologies, Inc.
10240 Old Columbia Road
Columbia, MD 21048
ITEM 2. IDENTITY AND BACKGROUND.
The reporting person's name is BioVenture Partners Limited Partnership,
a Delaware limited partnership, with a principal business and office address of
4 Milk Street, Portland, ME 04101. The reporting person's principal business is
that of manager of three venture capital funds.
During the last five years, the reporting person has not been convicted
in a criminal proceeding (excluding traffic violations and similar
misdemeanors). During the last five years, the reporting person has not been a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding been or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
The reporting person may be deemed to have acquired beneficial
ownership of more than five percent of the Common Stock of the Issuer as a
result of the Merger (defined in Item 4 below) in exchange for securities of
Brunswick Biomedical Corporation, a Massachusetts corporation ("BBC") owned by
three limited partnerships of which the reporting person is the general partner.
However, beneficial ownership by the reporting person is expressly disclaimed.
ITEM 4. PURPOSE OF TRANSACTION.
On November 20, 1996, pursuant to an Agreement and Plan of Merger dated
as of September 11, 1996, BBC merged with and into Survival Technology, Inc.
("STI"), with STI as the surviving corporation (the "Merger"). Immediately
following the Merger, STI changed its name to "Meridian Medical Technologies,
Inc."
3
<PAGE> 4
In accordance with the terms of the Merger, each share of BBC common
stock was exchanged for 2.1 shares of Common Stock of the Issuer, and each share
of BBC preferred stock was exchanged for 2.1 shares of Common Stock of the
Issuer and a warrant to purchase 0.4 shares of Common Stock of the Issuer (the
"Merger Warrant"). The Merger Warrants have an exercise price of $11.00 per
share of Common Stock and are exercisable for five years following the closing
of the Merger. In connection with the Merger, the Issuer also assumed the
obligations of BBC under outstanding stock options and warrants. Each of the
former BBC security holders has certain rights to registration with respect to
the Common Stock under the Securities Act of 1933, as amended.
The securities of the Issuer which the reporting person may be deemed
to beneficially own are held for investment purposes by their respective owners
(see description in Item 5 below). By virtue of its position as general partner
of these entities, the reporting person may continue to acquire, for investment
purposes, or dispose of securities of the Issuer beneficially owned by it in the
ordinary course of the reporting person's business. The reporting person
expressly disclaims beneficial ownership.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) The number of securities of the Issuer which the reporting person
may be deemed to beneficially own is 583,003. Of those, 184,888 represent
securities which the reporting person may be deemed to have the right to acquire
within 60 days. This aggregate represents approximately 19.9% of the Issuer's
outstanding class of such securities. The reporting person expressly disclaims
beneficial ownership of all securities reported in this Schedule.
(b) The reporting person does not have the sole power to vote and the
sole power to dispose of any of the shares of the Issuer's securities. By virtue
of its position as general partner, the reporting person may be deemed to share
the power to vote and share the power to dispose of the following common stock
of the Issuer with the entities so indicated: (i) 103,052 shares with
Commonwealth BioVentures III Limited Partnership ("Fund III"); (ii) 140,383
shares with Commonwealth BioVentures IV Limited Partnership ("Fund IV"); and
(iii) 339,568 shares with Commonwealth BioVentures V Limited Partnership ("Fund
V). However, the reporting person expressly disclaims beneficial ownership of
these shares. The business address of Fund III, Fund IV and Fund V is 4 Milk
Street, Portland, ME 04101. Fund III, Fund IV and Fund V are venture capital
funds. None of Fund III, Fund IV or Fund V during the last five years, have been
convicted in a criminal proceeding (excluding traffic violations and similar
misdemeanors) nor have and of them been a party to a civil proceeding of a
judicial or administrative body of competent jurisdiction and as a result of
such proceeding been or are subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities subject
to, federal or state securities laws or finding any violation with respect to
such laws.
4
<PAGE> 5
(c) Other than the acquisitions resulting from the Merger described in
Item 4, the reporting person has not effected any transactions in the securities
of the Issuer in the last sixty days.
(d) Except as otherwise indicated in this Schedule, no other persons
are known to have the right to receive or the power to direct the receipt of
dividends from, or the proceeds from the sale of, the securities.
(e) Not Applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
There are no contracts, arrangements, understandings or relationships
among the reporting person and any other person with respect to the securities
of the Issuer.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. None.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
BIOVENTURE PARTNERS LIMITED
PARTNERSHIP
BY: Commonwealth BioVentures,
Inc., its general partner
BY:
- ------------------------------ -----------------------------------
Date Robert G. Foster, President
5
